ADVERTISEMENT
Treatment Strategies for ER-Positive, HER2-Negative Early Breast Cancer
In this expert roundtable series, 3 leading breast cancer specialists discuss recent updates and considerations for choosing the optimal treatment approach for patients with ER-positive early breast cancer. The 4-part discussion series is led by Cynthia Ma, MD, Washington University School of Medicine, St Louis, Missouri, who is joined by Neelima Vidula, MD, and Seth Wander, MD, both from Massachusetts General Hospital, Boston.
Part 1:
Selecting Chemotherapy for Patients With ER-Positive, HER2-Negative Early Breast Cancer
This video discusses chemotherapy selection for patients with ER-positive early breast cancer, considerations for pre- and post-menopausal patients, and the role of anthracycline in this setting.
Part 2:
Selecting CDK4/6 Inhibitors for Patients With ER-Positive, HER2-Negative Early Breast Cancer
This video explores considerations for selection CDK4/6 inhibitors for patients with ER-positive early breast cancer and the latest data from the NATALEE and monarchE trials.
Part 3:
Selecting PARP Inhibitors for Patients With ER-Positive, HER2-Negative Early Breast Cancer
This video discusses considerations for selecting PARP inhibitors for patients with early-stage breast cancer, including those with ER-positive, HER2-negative disease, and how to decide between a PARP inhibitor and abemaciclib for patients with BRCA mutations.
Part 4:
Considerations for Endocrine Therapy for Patients With ER-Positive, HER2-Negative Early Breast Cancer
This video examines data surrounding ovarian function suppression in premenopausal and post-menopausal patients with ER-positive, HER2-negative breast cancer, as well as considerations regarding the duration of endocrine therapy in these patients.
